Vasoactive intestinal peptide prevents activated microglia‐induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma
Open Access
- 15 August 2003
- journal article
- fj express-summaries
- Published by Wiley in The FASEB Journal
- Vol. 17 (13), 1-17
- https://doi.org/10.1096/fj.02-1029fje
Abstract
In most neurodegenerative disorders, including multiple sclerosis, Parkinson's disease, and Alzheimer's disease, a massive neuronal cell death occurs as a consequence of an uncontrolled inflammatory ...Keywords
Funding Information
- Presbyterian Historical Society (041786-03)
This publication has 41 references indexed in Scilit:
- Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activationThe FASEB Journal, 2003
- Vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide inhibit chemokine production in activated microgliaGlia, 2002
- Immunobiology of vasoactive intestinal peptide (VIP)Immunology Today, 2000
- Regulation of the Heparan Sulfate Proteoglycan, Perlecan, by Injury and Interleukin‐1αJournal of Neurochemistry, 1999
- VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNγ synthesis by T cellsJournal of Neuroimmunology, 1999
- Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Tumor Necrosis Factor α Transcriptional Activation by Regulating Nuclear Factor-kB and cAMP Response Element-binding Protein/c-JunPublished by Elsevier ,1998
- Development of High Affinity Selective VIP1 Receptor AgonistsPeptides, 1997
- Polymorphonuclear leukocytes in brain parenchyma after injury and their interaction with purified astrocytes in cultureGlia, 1993
- Increased glutamate uptake and glutamine synthetase activity in neuronal cell cultures surviving chronic hypoxiaGlia, 1990
- Glucocorticoid mechanisms in acute spinal cord injury: A review and therapeutic rationaleSurgical Neurology, 1982